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Abstract
We investigated BRCAness in the biopsy and surgical specimens from 73 patients with breast cancer, taken
before and after taxane-containing neoadjuvant chemotherapy. All tumors that progressed on taxane-
containing regimens had a poor prognosis; all had BRCAness and most were triple negative. Identifying
BRCAness can help predict the response to taxane-containing regimens.
Background: To provide optimal treatment of heterogeneous triple negative breast cancer (TNBC), we need
biomarkers that can predict the chemotherapy response. Patients and Methods: We retrospectively investigated
BRCAness in 73 patients with breast cancer who had been treated with taxane- and/or anthracycline-based
neoadjuvant chemotherapy (NAC). Using multiplex, ligation-dependent probe ampliﬁcation on formalin-ﬁxed core
needle biopsy (CNB) specimens before NAC and surgical specimens after NAC. BRCAness status was assessed with
the assessor unaware of the clinical information. Results: We obtained 45 CNB and 60 surgical specimens from the
73 patients. Of the 45 CNB specimens, 17 had BRCAness (38.6% of all subtypes). Of the 23 TNBC CNB specimens,
14 had BRCAness (61% of TNBC cases). The clinical response rates were signiﬁcantly lower for BRCAness than for
non-BRCAness tumors, both for all tumors (58.8% vs. 89.3%, P ¼ .03) and for TNBC (50% vs. 100%, P ¼ .02). All
tumors that progressed with taxane therapy had BRCAness. Of the patients with TNBC, those with non-BRCAness
cancer had pathologic complete responses signiﬁcantly more often than did those with BRCAness tumors
(77.8% vs. 14.3%, P ¼ .007). After NAC, the clinical response rates were signiﬁcant lower for BRCAness than for
non-BRCAness tumors in all subtypes (P ¼ .002) and in TNBC cases (P ¼ .008). After a median follow-up of 26.4
months, 6 patients—all with BRCAness—had developed recurrence. Patients with BRCAness had shorter
progression-free survival than did those with non- BRCAness (P ¼ .049). Conclusion: Identifying BRCAness can help
predict the response to taxane, and changing regimens for BRCAness TNBC might improve patient survival. A larger
prospective study is needed to further clarify this issue.
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response (pCR), which is reportedly a surrogate marker for overall
survival in TNBC.2,3 However, approximately 20% of patients with
TNBC will develop progression during NAC, especially those
receiving taxane regimens, and have a very poor prognoses.4,5
Diagnostic imaging studies and immunohistochemical and histo-
logic studies cannot distinguish between resistant and sensitive
TNBC tumors. Therefore, quick, accessible, and reproducible
biomarkers are needed to identify the optimal chemotherapeutic
regimens for patients with this heterogeneous disease.
Recent randomized trials have shown that adding carboplatin to
anthracycline and taxane for NAC improves the pCR rates for TNBC;
2 meta-analyses found similar effects from adding platinum agents to
NAC regimens.6-9 However, adding carboplatin to standard NAC
increases the incidence of adverse events, leading to greater rates of
discontinuation and dosemodiﬁcation.Whether carboplatin should be
added to, or substituted for, standard NAC regimens is unclear; thus,
markers that can predict the response to standard NAC are needed.
“BRCAness” refers to some sporadic cancers that share phenotypic
characteristics with tumors that carry BRCA1/2 mutations (BRCA-
Mut), such as methylation of BRCA1/2 promoters and low BRCA1
gene expression.10 Double-strand DNA breaks (DSBs) are repaired
by homologous recombination, mediated by the products of BRCA1
and BRCA2 and by nonhomologous end-joining. Single-strand
breaks are repaired by the base-excision repair pathway, which is
regulated by poly-ADP ribose polymerase (PARP) 1 and by nucleo-
tide exon repair mechanisms. Therefore, because BRCAMut tumors
cannot repair DSBs induced by agents such as bifunctional alkylators
and platinum salts, they are hypersensitive to DSB-inducing agents
and probably to PARP inhibitors.11-14 Assessment of BRCAness
using array comparative genomic hybridization (aCGH) or multiplex
ligation-dependent probe ampliﬁcation (MLPA) has recently been
described.15 Patients with BRCAness tumors survive longer when
treated intensively with alkylating agents as adjuvant chemo-
therapy.15 Although germline mutations in BRCA1 and BRCA2
genes have been associated with  15% of TNBC cases,16,17 MLPA
assessments of BRCA status have indicated that these mutations are
seen in approximately two thirds of TNBC cases.18 The number of
those who will beneﬁt from targeted chemotherapy regimens
and/or PARP inhibitors might be larger when using BRCAness,
rather than BRCA1/2 mutation status, as the determinant.
Emerging preclinical and some clinical studies have indicated that
BRCA-associated tumors tend to be resistant to taxanes.16,17
Mammary tumors of BRCAMutþ mice are resistant to doxoru-
bicin and docetaxel but not to cisplatin.16 An in vitro study has
shown a BRCAMutþ breast cancer cell line to be resistant to tax-
ane.1 BRCAMutþ hormone receptorepositive metastatic breast
cancer has been shown to be less sensitive to taxane.17 However, to
our knowledge, the association between taxane response and
BRCAness has not been previously reported.
The present study investigated whether BRCAness can predict
the response to taxane treatment in patients with breast cancer
treated with NAC.
Patients and Methods
Patients
All the patients who received NAC with either taxane and/or
anthracycline for primary breast cancer from October 2010 toMarch 2013 at Showa University Hospital Breast Center were
included in the present retrospective study. Most of these patients
had been in randomized controlled trials comparing the efﬁcacy
and feasibility of docetaxel followed by 5-ﬂuorouracil, epirubicin,
and cyclophosphamide (FEC) every 3 weeks or weekly albumin-
bound paclitaxel (nab-paclitaxel) followed by FEC as NAC for
patients with human epidermal growth factor receptor 2 (HER2)e
negative breast cancer. Before these trials had started, the regimen
administered was docetaxel and cyclophosphamide every 3 weeks.
For HER2þ tumors, the regimen was FEC followed by docetaxel
and trastuzumab. Relevant clinicopathologic information was
collected from our database and medical records. Clinical responses
were determined by ultrasonography and magnetic resonance
imaging using the Response Evaluation Criteria in Solid Tumors,19
with imaging performed before NAC and at the end of the ﬁrst
and second cycles. The clinical response rate (cRR) was deﬁned as
the sum of the clinical complete and partial responses (PRs). In
patients whose tumors progressed, the regimen was stopped, and
either surgery performed or a second-line regimen substituted.
The patients underwent surgery approximately 1 month after
completing the last NAC cycle. The surgical procedures were
determined according to the diagnostic imaging ﬁndings after NAC
completion. Sentinel lymph node biopsy was performed in patients
whose lymph nodes had been clinically negative before NAC.
The institutional review board of our university approved present
the study.
Pathology
The tumor subtypes were routinely determined immunohis-
tochemically before NAC, using core needle biopsy (CNB) speci-
mens. The cancer specimens were deﬁned as HER2þ when HER2
immunohistochemical staining was 3þ or ﬂuorescence in situ hy-
bridization (FISH) showed HER2 gene ampliﬁcation. Estrogen
receptor (ER) and progesterone receptor (PgR) positivity was
deﬁned as  1% of tumor cells staining positive for ER or PgR. A
pCR was deﬁned as complete remission of the invasive components
of cancer in the breast.20
MLPA Method
BRCAness was determined by examination of formalin-ﬁxed,
parafﬁn-embedded (FFPE) CNB specimens taken before
NAC and surgical specimens taken after NAC. DNA was isolated
from the tumor tissue using the QIAamp DNA FFPE Tissue
Kit (Qiagen, Hilden, Germany) after macrodissection. Classiﬁca-
tion of BRCAness was performed using MLPA with the Pro-
bemix P376-B2 BRCA1ness (MRC-Holland, Amsterdam, The
Netherlands), as previously reported by Oonk et al.13 MLPA
was performed at Falco Biosystems (Kyoto, Japan) as a part of
collaborative research and according to the manufacturer’s
instructions. For each sample, the relative copy number ratios for
the 38 target-speciﬁc probes, compared with the reference samples
of human genomic DNA (Promega, Madison, WI), were calcu-
lated using the Coffalyser.Net software and were used for the
prediction analysis for microarrays, with the training set generated
by MRC-Holland. Each sample was analyzed twice. The average
scores were used for this analysis. BRCAness status was analyzed
by experienced laboratory scientists who were unaware of theClinical Breast Cancer February 2015 - 81
Table 1 Relevant Patient and Tumor Characteristics
Variable
All NAC Patients
(n [ 73)
CNB Available
(n [ 45)
Age (years) 42.0 (27-75) 42.3 (27-73)
Tumor size before NAC
T1 10 (13.7) 5 (11.1)
T2 43 (58.9) 28 (62.2)
T3 15 (20.5) 9 (20.0)
T4b 5 (6.8) 3 (6.7)
Histologic type before NAC
IDC 68 (93.2) 40 (88.9)
ILC 2 (2.7) 2 (4.4)
Apocrine 1 (1.4) 1 (2.2)
Mucinous 2 (2.7) 2 (4.4)
Subtype before NAC
Triple negative 26 (35.6) 23 (51.1)
ER/HER2þ 13 (17.8) 7 (15.6)
ERþ/HER2þ 7 (9.6) 2 (4.4)
ERþ/HER2 27 (37.0) 13 (28.9)
Regimen
Taxane þ anthracycline 48 (65.8) 32 (72.7)
Taxane 12 (16.4) 10 (22.7)
Taxane þ anthracycline
þ trastuzumab
13 (17.8) 3 (4.5)
Clinical response
CR 7 (9.6) 7 (15.9)
PR 47 (64.4) 28 (61.4)
SD 14 (19.2) 5 (11.4)
PD 5 (6.8) 5 (11.4)
Pathologic response
pCR 11 (15.1) 11 (25.0)
Other 62 (84.9) 34 (75.0)
Pathologic nodal status
N0 46 (61.3) 32 (71.1)
N1-N3 18 (24.7) 8 (17.8)
N4 or greater 9 (12.3) 5 (11.1)
Data presented as mean (range) or n (%).
Abbreviations: CNB ¼ core needle biopsy; CR ¼ complete response; ER ¼ estrogen receptor;
HER2 ¼ human epidermal growth factor receptor 2; IDC ¼ invasive ductal carcinoma; ILC ¼
invasive lobular carcinoma; NAC ¼ neoadjuvant chemotherapy; pCR ¼ pathologic complete
response; PD ¼ progressive disease; PR ¼ partial response; SD ¼ stable disease.
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positivity was 0.4.
BRCA1/2 Germline Mutation
Genetic counseling was recommended for patients suspected of
having BRCA germline mutations, in accordance with the National
Comprehensive Cancer Network guidelines. One half of them
underwent genetic testing. BRCA1/2 mutation analysis was per-
formed at Falco Biosystems (Kyoto, Japan) using the direct
sequencing method on patient blood samples. If this initial analysis
did not detect a mutation, the sample was checked again for
BRCA1/2 genetic rearrangements using MLPA.
Statistical Analysis
Fisher’s exact test was used to assess the differences between the
BRCAness and non-BRCAness groups. Student’s t test was used
to assess the differences between the BRCAness and non-
BRCAness groups for the Ki-67 index. The log-rank test was
used to evaluate the differences in relapse-free survival. The soft-
ware used was EZR on R21 for Fisher’s exact test and SPSS for the
log-rank test.
Results
Of the 73 patients who underwent NAC, surgical specimens
were available from 60 patients and CNB specimens from
45 patients for BRCAness analysis (Table 1). In 13 patients who
had a pCR, BRCAness could not be measured on the surgical
specimens. Also, 28 CNB specimens were not available, because the
CNBs had been performed by the patients’ family doctor. The
patients’ overall mean age at the diagnosis of breast cancer was
42.0 years (range, 27-75 years). Nine patients underwent genetic
testing for BRCA1/2 germline mutation after genetic counseling;
5 patients carrying the BRCA1 germline mutation and 2 with the
BRCA2 mutation were identiﬁed among the 73 patients. Of these
5 patients, 4 with the BRCA1 germline mutation and 1 with the
BRCA2 mutation were BRCAness positive.
Of the 45 CNB specimens of all tumor subtypes, 17 (23.3%)
were BRCAness positive. Of the 23 CNB specimens with TNBC,
14 (60.9%) were BRCAness positive. The other 3 BRCAness
tumors without TNBC included 2 HER2-enriched tumors and
1 ERþ tumor. One tumor that was HER2þ before NAC had
changed to TNBC after NAC. Another HER2þ tumor was
immunohistochemically 3þ but had been FISH-negative before
NAC. The tumor tested positive after NAC. The only ERþ tumor
remained ERþ after NAC.
We analyzed the association between BRCAness found in the
CNB specimen and the cRR for taxane-containing regimens
(Table 2). The cRR was signiﬁcantly lower for BRCAness tumors of
all subtypes (58.8%) than for non-BRCAness tumors (89.3%;
P ¼ .027) and, more strikingly so, for BRCAness TNBC (50%)
than for non-BRCAness TNBC (100%; P ¼ .019). All the
non-BRCAness TNBC cases responded well to taxane regimens.
Five patients experienced progressive disease (PD) during taxane-
containing NAC (Table 3), including 4 with BRCAness TNBC
and 1 with a mucinous ERþ/PgRþ carcinoma. CK5/6 and
epidermal growth factor receptor were not effective in predicting the
response to taxane.Clinical Breast Cancer February 2015Patients with non-BRCAness TNBC achieved pCRs signiﬁcantly
more often (77.8%) than did those with BRCAness TNBC (14.3%;
P ¼ .0066; Table 4). Before NAC, the patients with BRCAness or
non-BRCAness TNBC did not differ signiﬁcantly in any other
clinicopathologic factor.
Of the 60 surgical specimens taken after NAC, 9 (15.0%) were
BRCAness positive. Analysis of the association between BRCAness
subtype and the cRR after taxane-containing regimens showed that,
for all subtypes, the cRR was signiﬁcantly lower for BRCAness
tumors (22.2%) than for non-BRCAness tumors (78.4%;
P ¼ .002) and more so for BRCAness TNBC tumors (14.3%) than
for non-BRCAness TNBC tumors (88.9%; P ¼ .008).
Table 4 Relationships Between BRCAness Before, and Path-
ologic Responses to, Neoadjuvant Chemotherapy for
Triple Negative Breast Cancer
Variable
BRCAness
(n [ 14)
Non-BRCAness
(n [ 9) P Value
Average age (years) 46 (27-62) 48 (37-59) NS
Tumor size before NAC NS
T1 1 (7.1) 2 (22.2)
T2 11 (78.6) 7 (77.8)
T3 1 (7.1) 0 (0)
T4b 1 (7.1) 0 (0)
Histologic grade NS
1-2 5 (35.7) 3 (33.3)
3 8 (57.1) 5 (55.6)
ND 1 2
Pathologic response .0066
pCR 2 (14.3) 7 (77.8)
Other 12 (85.7) 2 (22.2)
Pathologic nodal status NS
N0 9 (64.3) 7 (77.8)
Nþ 5 (35.7) 2 (22.2)
Average Ki-67 (%) 66.0 58.1 NS
Recurrence NS
Yes 5 (35.7) 0 (0)
No 9 (64.3) 9 (100)
Data presented as average (range) or n (%).
Abbreviations: NAC ¼ neoadjuvant chemotherapy; ND ¼ not determined; NS ¼ not signiﬁcant;
pCR ¼ pathologic complete response.
Table 2 Relationships Between BRCAness Before Neo-
adjuvant Chemotherapy and Clinical Responses to
Taxane for All Subtypes and for Triple Negative
Breast Cancer
Clinical
Response
BRCAness
(%)
Non-BRCAness
(%)
P Value
(Fisher’s Exact
Test)
All .027
CRþPR 10 (58.8) 25 (89.3)
SDþPD 7 (41.2) 3 (10.7%)
TNBC .019
CRþPR 7 (50) 9 (100)
SDþPD 7 (50) 0 (0)
Abbreviations: CR ¼ complete response; PD ¼ progressive disease; PR ¼ partial response;
SD ¼ stable disease; TNBC ¼ triple negative breast cancer.
Sadako Akashi-Tanaka et alThe median follow-up duration from the initiation of NAC was
26.4 months. Of the 26 patients with TNBC before NAC, 6
developed a recurrence, including 3 with locoregional recurrence
and 3 with distant metastases (1 patient each with brain, lung, or
liver metastases). All 3 locoregional recurrences had developed after
radical mastectomy for BRCAness TNBC. The patients with
BRCAness had worse progression-free survival than those with non-
BRCAness (58% vs. 100%, P ¼ .049).
Figure 1 shows the BRCAness changes in TNBC after NAC. Of
the 14 BRCAness TNBC tumors before NAC, 5 remained
BRCAness positive after NAC. Of these 5 patients, 3 had PD and 2
stable disease; 3 developed a recurrence. Of the 14 BRCAness
TNBCs before NAC, 7 tested negative after NAC. Their responses
to taxane varied from a PR to PD. In contrast, of 9 tumors that were
non-BRCAness before NAC, 7 (77.8%) had achieved a pCR and 2
had a clinical PR.
Discussion
The results of the present study indicate that BRCAness tumors
have a signiﬁcantly poorer response to taxane regimens than do
non-BRCAness tumors. Originally, BRCAness was identiﬁed by
comparing BRCAMut tumors with sporadic TNBC tumors using
the aCGH method. However, MLPA probes are now commercially
available. Adjuvant therapy with high-dose, platinum-based, alky-
lating agents is reportedly more effective for BRCAness tumors
(according to aCGH) than conventional chemotherapy; this has
not been true for non-BRCAness tumors.11 The assessment ofTable 3 Characteristics of Tumors That Developed Progressive Dise
Pt.
No. NAC Response
Germline
Mutation BRCAness ER
1 PD @ Doce 1 cycle (FEC) BRCA2 þ 
2 PD @ Doce 1 cycle NP þ 
3 PD @ Doce 2 cycle (FEC) NP þ 
4 PD @ nabPTX 7 cycle (FEC) BRCA1 þ 
5 PD @ TC 3 cycle NP  þ
Abbreviations: þ ¼ positive;  ¼ negative; Doce ¼ docetaxel; EGFR ¼ epidermal growth factor re
human epidermal growth factor receptor 2; nabPTX ¼ albumin-bound paclitaxel; NAC ¼ neoadjuvant
Pt. No. ¼ patient number; TC ¼ docetaxel, cyclophosphamide.BRCAness using MLPA and aCGH is reportedly concordant (ac-
curacy 94%) and also predicts similar survival beneﬁts with
intensive alkylating agent chemotherapy.15 However, with con-
ventional dose anthracycline chemotherapy, the prognoses of
BRCAness and non-BRCAness tumors are similar.13 Patients with
BRCAness tumors have substantially better outcomes after adjuvant
DSB-inducing chemotherapy.11 Together with our ﬁndings, these
results imply that administering platinum salts according to
BRCAness status in patients with TNBC will be preferable to
administering them to all TNBC patients. Our recommended
treatment strategy is that patients with BRCAness tumors receive
platinum- and anthracycline-based chemotherapy and that patients
with non-BRCAness TNBC receive standard taxane- andase During Taxane-Based Neoadjuvant Chemotherapy
PgR HER2 Ki-67 EGFR CK-56
Pathologic
Response
 1 80-90 þ þ Poor response
 0 60-70 þ  No response
 0 60-70 þ  No response
 0 50-60   Poor response
þ 1 5 NP NP No response
ceptor; ER ¼ estrogen receptor; FEC ¼ 5-ﬂuorouracil, epirubicin, cyclophosphamide; HER2 ¼
chemotherapy; NP ¼ not performed; PD ¼ progressive disease; PgR ¼ progesterone receptor;
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Figure 1 Changes in BRCAness Status After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer and Relationship to Clinical
Response
Abbreviations: CR ¼ complete response; NAC ¼ neoadjuvant chemotherapy; ND ¼ no data; NS ¼ not signiﬁcant.
BRCAness Predicts Taxane Resistance
84 -anthracycline-based chemotherapy. Adding a PARP inhibitor, for
both patients with BRCA1 germline mutations and those with
BRCAness, might improve survival12 and warrants additional
study.
The ability to predict resistance to taxane treatment by BRCA-
ness status was shown in all our patients, regardless of subtype, but
especially in the TNBC subgroup. The reported rates of BRCAness
assessed using the aCGH and MLPA methods were 18% for all
subtypes and 69% for TNBC.11,22 Approximately two thirds of
TNBC tumors in the present study were BRCAness positive, but
only a few non-TNBC tumors were BRCAness positive, corre-
sponding with the results from previous reports. Therefore, we
recommend assessing BRCAness status only for patients with
TNBC.
The mechanisms for resistance to taxane by BRCAness tumors
have not yet been established. Intact BRCA1 function might play an
important role in the optimal response to taxane-based therapy.23 A
BRCA1-induced increase in the c-Jun N-terminal kinase pathway
causes apoptosis in BRCA1-expressing cells treated with
paclitaxel.24,25
Tumors with low BRCA1 expression, demonstrated by immu-
nohistochemistry, have had shorter times to progression when
treated with taxane-containing regimens.26 However, this ﬁnding
has not been conﬁrmed by other investigators, possibly because of
the poor reproducibility of the BRCA1 antibody assays. A homol-
ogous recombination deﬁciency assay reported in 2013,27 which
performs genome-wide, single-nucleotide polymorphism analysis
using Affymetrix molecular inversion probe arrays of DNA
sequencing, is also effective for selecting likely responders to neo-
adjuvant carboplatin, gemcitabine, and iniparib.
Reportedly, the pCR rate after a NAC regimen of dose-dense
cyclophosphamide and doxorubicin was signiﬁcantly greater in
BRCA1-mutated tumors (63%) than in non-BRCA1emutated
tumors (33%). The pCR rate also tended to be greater in
BRCAness than in non-BRCAness tumors (35% vs. 21%).22
However, these investigators also reported that the recurrence
rates after adjuvant chemotherapy with anthracycline-
based regimens did not differ between these groups. In our
study, patients with BRCAness tumors treated with taxaneClinical Breast Cancer February 2015and/or anthracycline had a poor prognosis, developing both PD
and PRs. These discrepancies in outcomes likely reﬂect the
different regimens used.
Paluch-Shimon et al28 reported that BRCA1/2-associated TNBC
had a better pCR rate than TNBC in noncarriers (61% vs. 39%;
P ¼ .007) after dose-dense NAC with an anthracycline and a
taxane, opposite the results in our study. They also reported that
the pCR was not associated with the long-term outcome in
BRCA1/2-associated TNBC, unlike non-BRCAeassociated
TNBC, probably owing to enrichment of the cancer stem cells
in BRCA1/2 tumors.28 In our study, all 6 patients with tumor
relapse had BRCAness-positive tumors and no pCR response.
In contrast, patients with a pCR had a better prognosis. Only 7 of
our patients who had BRCA1/2 germline mutations, 4 of whom
(57%) achieved a pCR, and none of whom relapsed. Two of the
patients with BRCA1/2-associated breast cancer who did not
achieve a pCR developed a relapse. In our small series, a pCR
also seemed to be associated with better long-term outcomes in
patients with BRCA1/2-associated breast cancer. The characteristic
differences in terms of chemosensitivity and cancer stem cells
among BRCA1/2-associated TNBC cases and BRCAness cases
should be investigated further.
In the present study, we used a cutoff ratio for BRCAness of 0.4.
However, in the original report, the cutoff point was 0.5.11 The
scores in about 75% of the BRCAness tumors were > 0.7, but
approximately 80% of the non-BRCAness tumors scored < 0.2.
Thus, these 2 categories are easy to differentiate. The score of 1
patient with PD after 2 cycles of docetaxel was 0.42 before NAC
and 0.86 after NAC. In no other patient did the BRCAness status
change from negative to positive after NAC. Therefore, we applied
this cutoff point. A larger scale study is needed to clarify the
appropriate cutoff point.
The present study had some limitations. The ﬁrst was that it was
a small retrospective analysis. Retrospective validation studies using
NAC cohorts from other hospitals are ongoing. A larger prospective
study is needed to validate our ﬁndings. Second, some data
concerning BRCAness before NAC were unavailable, because we
did not perform new biopsies in patients who had been already
diagnosed with breast cancer at other hospitals.
Sadako Akashi-Tanaka et alConclusion
Identifying the BRCAness status can help predict the response to
taxane, and changing regimens for BRCAness TNBC might
improve patient survival. A larger prospective study is needed to
further clarify this issue.
Clinical Practice Points
 Approximately one ﬁfth of TNBC tumors progress during NAC,
especially those treated with taxane-containing regimens.
 Adding platinum salts to standard NAC regimens signiﬁcantly
improves the pCR rate in patients with TNBC. Although
whether platinum salts should be added to, or substituted for, the
standard regimen is controversial.
 We found that most patients with non-BRCAness TNBC
achieved a pCR rate using the standard regimen; however,
patients with BRCAness TNBC were more likely to develop PD
and have a worse prognosis.
 Adjuvant therapy with high-dose, platinum-based alkylating
agents is reportedly more effective than conventional chemo-
therapy for BRCAness tumors but not for non-BRCAness
tumors. Therefore, platinum salts for TNBC should be
selected according to the BRCAness status rather than adding it
to the regimens of all patients with TNBC.
 The method we used is clinically feasible and requires only
commercially available MLPA probes.
 In the future, this biomarker might also assist in the selection of
patients with TNBC to receive a PARP inhibitor.Acknowledgments
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